INFORMATION STATEMENT

Guidance and best practices for nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An Information Statement from ASNC and SNMMI

Hicham Skali, MD, MSc,a,b Venkatesh L. Murthy, MD, PhD,c Mouaz H. Al-Mallah, MD, MSc,d Tim M. Bateman, MD,e Rob Beanlands, MD,f Nathan Better, MD,g Dennis A. Calnon, MD,h Vasken Dilsizian, MD,i Alessia Gimelli, MD,j Robert Pagnanelli, BSRT(R)(N), CNMT, NCT,k Donna M. Polk, MD, MPH,b Prem Soman, MD, PhD,l Randall C. Thompson, MD,e Andrew J. Einstein, MD,m and Sharmila Dorbala, MD, MPHa,b

a Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
b Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
c Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI
d Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX
e Saint Luke’s Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, MO
f Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Canada
g Departments of Nuclear Medicine and Cardiology, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia
h OhioHealth Heart and Vascular Physicians, Columbus, OH
i Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD
j Fondazione Toscana Gabriele Monasterio, Pisa, Italy
k Department of Radiology, Duke University Health System, Durham, NC
l Division of Cardiology, Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA
m Department of Medicine, Cardiology Division, and Department of Radiology, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, NY

Received Mar 27, 2020; accepted Mar 27, 2020

doi:10.1007/s12350-020-02123-2

INTRODUCTION

Since its emergence in December 2019, Coronavirus Disease 2019 (COVID-19) has profoundly affected healthcare systems worldwide. No aspect of medical practice has been untouched, and each area of practice has unique considerations to be taken into account.1–9 COVID-19 is associated with increased risks in patients with cardiovascular disease and provides unique challenges for their care, as well as for the care of all patients in healthcare facilities and the staff in these facilities.10,11 As prevention is of utmost importance to contain the spread of COVID-19, all non-urgent nuclear cardiology studies should be postponed and only

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12350-020-02123-2) contains supplementary material, which is available to authorized users. This article is being jointly published in The Journal of Nuclear Medicine (https://doi.org/10.2967/jnumed.120.246686) and the Journal of Nuclear Cardiology (https://doi.org/10.1007/s12350-020-02123-2).

Reprint requests: Sharmila Dorbala, MD, MPH, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115; sdorbala@bwh.harvard.edu

J Nucl Cardiol
1071-3581/$34.00
Copyright © 2020 Society of Nuclear Medicine & Molecular Imaging and the American Society of Nuclear Cardiology.
urgent studies performed whenever clinically appropriate to expedite management of outpatients, as well as assessment and disposition of inpatients and emergency department patients, and expand hospital capacity, with precautions to minimize exposure of healthcare professionals and patients. In this Information Statement, the American Society of Nuclear Cardiology (ASNC) and Society of Nuclear Medicine and Molecular Imaging (SNMMI) address the practice of nuclear cardiology in the setting of the current COVID-19 pandemic reflecting the perspectives of diverse practices across the United States and worldwide.

The document is organized around steps for protection of healthcare personnel and the patient, using the patient’s journey through the nuclear cardiology laboratory, for inpatients, outpatients, and emergency department patients. We emphasize that many of these recommendations are practice based, and not systematically tested, and must be considered in the context of following state, local public health, and institutional infection control policies which may change day by day in this rapidly changing outbreak. This guidance is provided as an initial response to this pandemic and changes could be necessary if this becomes chronic or seasonal.

GENERAL PRINCIPLES FOR COVID-19 PROTECTION

Several general principles have been suggested by the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) with key goals to reduce mortality and morbidity, minimize disease transmission, protect healthcare professionals, and preserve healthcare system functioning. In specific, some of these recommendations include

• Distancing.
• Hand hygiene.
• Rescheduling non-urgent visits.
• Rescheduling elective surgeries and procedures.
• Using separate spaces for patients with known or suspected COVID-19 to prevent spread.
• Ensuring supplies are available.
• Promoting use of telehealth.

PROTECTION OF HEALTHCARE PERSONNEL

All practices should take steps to minimize the risk of COVID-19 exposure to healthcare personnel and patients during the performance of nuclear cardiology procedures. Below is a list of procedures recommended for healthcare professionals, compiled from various institutions. These apply at all times in the workplace and throughout the patient journey.

• Screen staff, patients, and visitors before they enter the department.
• Minimize non-essential visitors into the department.
• Record symptoms at the start of the shift.
• Record temperature daily as per local policies and standards.
• Use personal protective equipment (PPE) for healthcare personnel, and if available for patients (due to concern of asymptomatic transmission of COVID-19), as per local policies and standards.
• Maintain strict hand hygiene.
• Maintain 6 feet distance in all patient/staff interactions when possible.
• Minimize crowding in workplace.
• Work remotely whenever feasible.
• Use of virtual conference tools for meetings and educational conferences.
• Rotating staff schedules for onsite and offsite work.
• Training in local infection control recommendations.

ADAPTING NUCLEAR CARDIOLOGY PRACTICE DURING THE COVID-19 PANDEMIC

Patients referred for nuclear cardiology procedures are frequently greater than 60 years of age and have other comorbidities (e.g., hypertension, diabetes, chronic lung disease, and chronic renal disease) that place them at a high risk for adverse outcomes with COVID-19. The various steps to minimize patient and healthcare professional exposure to COVID-19 are listed below, tracking the patient journey from pre-procedure planning before the test, to steps taken on arrival for the test, during the test, and after the test for image interpretation and reporting (Figure 1).

General considerations before the patient arrives for the test

Prior to the patient arriving for an examination, the laboratory team needs to ascertain: 1) the level of risk of the patient transmitting COVID-19 to laboratory personnel, and 2) the urgency of performing the test, whether it can be safely deferred, and if so, for how long. It is important to contact patients the day prior to the scheduled nuclear cardiology testing to screen
patients by history following latest local infection control recommendations for COVID-19 exposure risk. It is important to contact patients the day prior to the scheduled nuclear cardiology testing to ensure that the patient is not experiencing clinical signs (fever) or symptoms (cough, dyspnea, unusual fatigue, myalgia, diarrhea, anosmia, hyposmia, dysgeusia, or ageusia) suggesting possible occult COVID-19 infection, and that they have not been exposed to any case or high-risk subjects in the preceding 2 weeks, and have not travelled to high COVID risk areas (Table 1). An equally important consideration is the potential risk of the patient being exposed to COVID-19 infection through exposure to the nuclear laboratory equipment and laboratory personnel. Suggest patients to arrive for the test alone, if feasible. If the patient must be accompanied, the accompanying person should also be screened for history of COVID-19 exposure risk. Depending on

**Table 1.** Screening checklist

| Question                                                                 |
|-------------------------------------------------------------------------|
| Have you had a fever?                                                   |
| Have you had a cough?                                                   |
| Have you had difficulty breathing?                                      |
| Have you been unusually tired?                                          |
| Have you had muscle aches?                                              |
| Have you had diarrhea recently?                                         |
| Is your sense of smell less than it usually is?                         |
| Is your sense of taste less than it usually is?                         |
| Have you been exposed to any person with the virus in the last 2 weeks?  |
| Have you been exposed to any person who has a high risk of getting the virus, in the last 2 weeks? |
| Have you travelled to any place where a lot of people have COVID-19?     |

**Figure 1.** Key steps to minimizing COVID-19 exposure during the patient’s journey through the nuclear cardiology laboratory.
### Table 2. Some examples of nuclear cardiology studies and selection

| Indication                                                                 | Urgency          | Notes                                                                 |
|----------------------------------------------------------------------------|------------------|----------------------------------------------------------------------|
| **Myocardial perfusion imaging for ischemic heart disease**                | Priority 1       | Perform test using precautions                                        |
| Recent acute coronary syndrome: evaluation of ischemia in moderate- to high-risk patients considered for urgent coronary revascularization |                  |                                                                      |
| New or accelerating symptoms: Canadian Cardiovascular Society Class II–IV where diagnosis of CAD is uncertain (intermediate pretest likelihood), or where suspicion of CAD, is high but coronary angiography has greater risk | Priority 1       | Perform test using precautions                                        |
| Preoperative evaluation: evaluation of ischemia in moderate- to high-risk patients in whom surgical procedure is urgent and revascularization is an option | Priority 1       | Perform test using precautions                                        |
| Stable angina: for evaluation of ischemia follow-up when there is no urgent revascularization plan | Priority 2 or 3  | Postpone test                                                         |
| 18F-FDG PET viability                                                     | Priority 1       | Perform test using precautions                                        |
| Patients with ongoing symptoms being considered for CABG in the next 2 weeks where viability imaging will impact revascularization decision (such as patients with multiple co-morbidities) | Priority 2 or 3  | Postpone test                                                         |
| Stable chronic ischemic cardiomyopathy evaluation prior to cardiac transplant listing | Priority 2 or 3  | Postpone test                                                         |
| 99mTc-PYP imaging for transthyretin cardiac amyloidosis                   | Priority 1 or priority 2 or 3 | Perform test in select cases or postpone test |
| Initial evaluation: Heart block or VT and suspected cardiac sarcoidosis   | Priority 1 or 2  | Perform test using precautions                                        |
| Follow-up evaluation: Known cardiac sarcoidosis on therapy               | Priority 2 or 3  | Postpone test                                                         |
| 18F-FDG PET for infective endocarditis                                    | Priority 1       | Perform test using precautions                                        |
| Initial evaluation: Suspected prosthetic or device infection              | Priority 2 or 3  | Postpone test                                                         |
| Follow-up evaluation: FDG PET prosthetic valve infective endocarditis     | Priority 2 or 3  | Postpone test                                                         |
| MUGA scan for LVEF estimation                                             | Priority 1       | Perform test using precautions                                        |
| Assessment of left ventricular function, as an alternative to echocardiography with short duration of patient-staff interaction | Priority 1       | Perform test using precautions                                        |
| Initial evaluation: Prior to initiation of cardiotoxic chemotherapy       | Priority 1       | Perform test using precautions                                        |
| Follow-up evaluation: Prior to subsequent chemotherapy                   | Priority 1       | Perform test using precautions                                        |
| Liver transplant: preoperative evaluation in patient with intermediate or high cardiovascular risk and poor life expectancy from liver disease without transplantation | Priority 1 or priority 2 | Perform test using precautions or postpone test |
| Kidney transplant: preoperative evaluation                               | Priority 2 or 3  | Postpone test                                                         |
| Heart transplant: Routine evaluation for transplant vasculopathy          | Priority 2 or 3  | Postpone test                                                         |

Priorities in this table are based on consensus. Laboratories should follow the principle that for tests that are performed as scheduled (Priority 1), the test should be expected to drive a meaningful treatment change that could be implemented in the immediate future and would have a clear short-term benefit. This might necessitate a discussion with the referring provider. Where multiple priorities are listed for a single indication, clinical judgment, and discussion with referring provider is recommended.

Priority 1: perform test as scheduled. Priority 2: postpone test by 2–4 months. Priority 3: postpone test by > 4 months. This applies primarily for subjects who are not COVID-19 positive.

*This applies to centers where active transplant surgeries are proceeding and a patient is listed with a status sufficient that they may receive an organ in the next few weeks.

*Most centers are temporarily not performing kidney transplantation at this time.

**CAD** coronary artery disease, **FDG** fluoro deoxy glucose, **LVEF** left ventricular ejection fraction, **COVID** coronavirus disease, **VT** ventricular tachycardia.
the prevalence of COVID-19 in the local community, some centers may institute additional policies, such as testing outpatients for COVID-19 infection before elective diagnostic procedures.

During this pandemic, with hospital resources stretched in many parts of the world, there is limited role for performing nuclear cardiac stress tests in patients who are known to have active COVID-19 virus infection. The results of nuclear cardiology procedures would be very unlikely to alter short-term patient management in most patients with active COVID-19 infection. Likewise, facilities need to exercise extreme caution in patients who have been exposed to COVID-19, especially those with recent, high-risk exposures.

In addition, during the COVID-19 pandemic, hospitals are making every effort to decrease the number of elective surgical and imaging procedures to conserve PPE. They are also attempting to conserve cleaning and decontamination chemicals as these resources are of limited supply. Thus, patients who do not have an urgent need for testing should have their testing deferred. Procedures with a potential to change management within the next few weeks and could impact short-term prognosis should be performed. Procedures that have a low probability of identifying serious abnormality that can change management acutely, for which benefit would primarily be over the intermediate or long term, can be postponed. Such classification of procedures requires clinical judgment and preferably discussion with the referring provider.

As the pandemic spreads into a community, many laboratory medical directors have taken the time to review patients’ medical records to assign the triage category. Some centers triage using a three-category scale (Table 2). Performance of imaging will be based on the guiding principle that imaging is appropriate per appropriate use criteria and will result in a change in patient management in the near term (Priority 1, perform as scheduled), intermediate term (Priority 2, postpone by 2–4 months) or long term (Priority 3, postpone > 4 months). Decisions are made based on clinical judgment on expected benefit to guide management, on the urgency of the test, and in discussion with the referring clinician. This list is not exhaustive and is meant to provide a few examples of tests that can be performed or postponed by 2–4 months or longer based on a discussion with the referring clinician. Laboratories should consider establishing such priority scales and follow the principle that the timing of the test relates to the urgency of the management decision being made.

Another more granular approach is to triage using a four-category scale: (1) those patients who have an urgent need for testing, (2) those who can safely defer testing for 1–2 months, (3) those in whom the test can be safely deferred for 2–3 months, and (4) elective (those in whom the test can be deferred for 4–6 months).

Contemporary electronic health records allow referring providers to indicate test priority at the time of test ordering. Patients whose exams are deferred should be given an explanation for this deferral, and urged to contact their provider if their condition changes. If possible, patients in whom the tests are deferred can be contacted on a regular basis by providers to confirm that they remain stable and that their condition has not deteriorated requiring an earlier test or different management. At the time this document was written, > 90% of planned outpatient tests have been postponed by 8 weeks in many centers.

**Considerations at the time of patient arrival for the test**

- Given the risk of transmission from asymptomatic carriers, all patient-facing staff in the waiting room and laboratory should wear a facemask at all times, if available.
- Upon arrival to the hospital/nuclear laboratory, question the patient again for COVID-19 exposure and risk as listed previously.
- Depending on local policies and available human and supply resources, consider measuring temperature of all patients at arrival to the healthcare facility and/or nuclear cardiology laboratory. Consider non-contact thermometer if available.
- If the patient has suspicious symptoms, staff in contact with the patient should don full PPE (mask, eye shielding, gown, and gloves) and provide a mask to the patient, following local direction for person under investigation (PUI). In many laboratories, these patients are being cancelled or rebooked depending on the course of the respiratory illness and the urgency of the test.
- Review the test indication with the nuclear laboratory team (Table 2).
- Physical distancing should be practiced in waiting areas, ideally with 6 feet (2 m) between persons.
- Limit interaction between inpatients and outpatients. For applicable laboratories, consider the possibility of separate imaging teams to handle inpatients and outpatients.
• It should be noted that in practices with combined nuclear medicine and nuclear cardiology operations, immunocompromised oncology patients may be in the same area and unduly exposed. Whenever possible, immunocompromised oncology patients should be separated from other patients, and have separate personnel attending to them for their testing.

Considerations during the test

1. Staff considerations
   • General principles of protection for healthcare personnel, as listed above, should be applied during the test.
   • For stress testing, PET, and SPECT studies, every effort should be made to minimize the number of staff in contact with the patient.
   • Handling of imaging in a COVID-19 positive patient is best performed using two technologists, one donning full personal protective equipment to attend to the patient, and the other to operate the scanner.

2. Room handling considerations
   • Proper infection control of the scanners as per institutional policies is mandatory.
   • For patients with confirmed active COVID-19, any testing should only be done if absolutely necessary. Consult with local infection control policies and consider scheduling them as last study of the day and on separate equipment if possible.
   • If a patient who has suspected or confirmed COVID-19 undergoes testing, thorough cleaning should then be performed by the designated “cleaning team” following infection control policies at that institution, with strict adherence to local guidelines.
   • The imaging room is appropriately cleaned, should be closed, and after a delay of 30-60 min (based on local practice recommendation) the imaging room can be terminally cleaned. After 1 hour, the room can be used again.
   • For patients not thought to be high risk for COVID-19 infection, after performing nuclear cardiology procedures all equipment (camera, table, chair) should be wiped down by staff using appropriate PPE (as per local policies and standards), and using appropriate cleaning material to include all surfaces in contact with the patient per local infection control policies.
   • For patients with known active COVID-19 or thought to be high risk for COVID-19, between patients, equipment including cameras, beds, and anything that has been in contact with ANY patient and/or staff should be decontaminated, using appropriate PPE (as per local policies and standards), by locally available cleansing agents and as per manufacturer’s recommendations. After scanning PUI or active COVID + patients, additionally, air/ventilation system disinfection may be performed per local infectious disease recommendations.
   • Regular cleaning of surfaces should also be performed using appropriate PPE (as per local policies and standards), including doorknobs, table surfaces, computer keyboards, telephones, and dictation equipment at least daily, and preferably, between users. This can be with locally available wipes or soaps, in keeping with institutional recommendations.
   • Also, minimize number of times staff go into and out of room to minimize use of PPE. This means extra attention to making patient comfortable, more time setting electrocardiogram leads, etc.
   • The stretcher, treadmill, blood pressure equipment, and infusion pumps should be cleaned after each test and sheets/linen replaced in compliance with local infection control recommendations.
   • Certain institutions in China are disinfecting the air-conditioning systems and using disinfectant fumigation of the healthcare facilities.

3. Protocol selection
   Given the need to minimize time of interaction between personnel and patients and maximize distance of interaction, selection of protocols that expedite testing is recommended.
   a. Imaging protocol selection
      • Select the protocol with the shortest duration of scan time and exposure to staff.
      • Consider using standard dose imaging with rapid imaging protocols.
      • Consider stress first imaging protocols.
      • Consider single-day imaging protocols.
      • Consider attenuation corrected imaging.
Cardiac PET if available may be preferred for rapid throughput and to help minimize time spent by the patient in the laboratory.

b. Stress testing protocol selection

- In accordance with your hospital policies, minimize contact for written consent (wiping, gloves, disposing pens), consider verbal consent, or written consent with minimized contact and exchanges of papers and pens (e.g., separate pens, gloves, wiping surfaces before and after use). Another possibility is to obtain consent using virtual visit or telehealth equipment from the patient before they come to the nuclear laboratory and document it in the electronic health record.
- Exercise stress testing, without or with vasodilator agents, should be generally avoided and a discussion with the referring provider may be reasonable to discuss this change.
- Pharmacological stress with vasodilators is preferred to minimize droplet exposure to exercise staff and minimize close contact between staff and patients.
- Regadenoson may be the preferred stress agent if available and not contraindicated for the patient, since it requires a single 10-s infusion, after which providers can maintain distance from the patient. For adenosine and dipyridamole stress testing, extra-long tubing can be used to keep distance between staff and patients.
- Automatic BP cuffs should be considered.
- If exercise testing is deemed necessary, personnel should use PPE as indicated per local institutional guidance.

c. 18F-fluorodeoxyglucose (FDG) PET scan

Patients referred for FDG PET for myocardial viability should wait in a separate room during the insulin–glucose manipulation procedure. Special precautions should be taken for minimizing potential exposure to and transmission of COVID-19 in patients with suspected endocarditis. FDG PET should be considered for endocarditis in a febrile patient with bacteremia as an alternative to transesophageal echocardiography, which carries a very high droplet risk exposure for operators.

Considerations after the test: Image Interpretation/Reporting

- Avoid multiple physicians/trainees in the same location if possible.
- Whenever possible use remote connection with screen sharing for image interpretation (using HIPAA compliant systems).
- CT images acquired for attenuation correction should be interpreted in the context of possible COVID-19 pulmonary findings. These images should be reviewed expeditiously before patient is discharged home. Early CT findings in COVID-19 can include bilateral and peripheral ground-glass and consolidative pulmonary opacities in the lungs. Careful review and discussion with chest imaging experts, referring physicians and infection control in these cases, is warranted.
- Avoid in-person image review with referring services and use remote reviewing or screen sharing wherever possible and/or telephone discussions.

POTENTIAL FOR RADIOTRACER SHORTAGES

Given the rapidly evolving pandemic and its impact on the world, shortage of medications and radiotracers is a possibility. At this time, no shortages are reported in the US but some countries in Asia have reported shortages of radiotracers. ASNC and SNMMI will attempt to provide ongoing guidance as information becomes available.

CONCLUSIONS

Changes to nuclear cardiology procedures are essential to minimize risk of viral exposure and transmission to healthcare personnel and patients during the COVID-19 pandemic. Nuclear cardiology laboratories are urged to follow local, state, public health, and institutional policies and these may change from day to day with the evolution of the pandemic. ASNC and SNMMI recommend that all non-urgent nuclear cardiology studies be postponed and urgent studies performed with careful attention to some of the precautions listed in this document. Our goal is to keep the patients and healthcare professionals safe while providing clinical useful information to guide the management of patients with heart diseases.
Disclosures

Dr. Bateman: Activities related to the present article: No relevant relationships. Activities not related to the present article: Research Grants: Bracco, GE Healthcare, Jubilant DraxImage. Consultant: AIM, AstraZeneca, Curium, GEHC. Royalties: SPECT and PET software products. Ownership interest: CVIT. Dr. Beanlands: Activities related to the present article: No relevant relationships. Activities not related to the present article: Grants/Honoraria from Jubilant DraxImage, LMI, GE Healthcare. Dr. Dorbala: Activities related to the present article: No relevant relationships. Activities not related to the present article: Grants and Honoraria from Pfizer and GE Healthcare. Institution has grants/grants pending from National Institutes of Health and International Atomic Energy Agency. Dr. Einstein: Activities related to the present article: No relevant relationships. Activities not related to the present article: Consultant for GE Healthcare and W. L. Gore and Associates; institution has grants/grants pending from National Institutes of Health, International Atomic Energy Agency, Canon Medical Systems, Roche Medical Systems, and W. L. Gore and Associates; received travel/accommodations/meeting expenses unrelated to activities listed from HeartFlow. Dr. Murthy: Activities related to the present article: No relevant relationships. Activities not related to the present article: Owns stock in General Electric and Cardinal Health and stock options in Ionetix. He has served as a paid advisor to Ionetix and Curiam. He has received research grants from Siemens and non-financial research support from INVIA Medical Imaging Solutions. He has received payment on behalf of Jubilant DraxImage for expert witness testimony. Dr. Soman: Activities related to the present article: No relevant relationships. Activities not related to the present article: Grantees of Jubilant DraxImage for expert witness testimony. Dr. Soman: Activities not related to the present article: Serves on the board of directors/governance committees of IONETIX, EDRNA, AARTI, and Demetra. He has received honorarium for educational activities from IQVIA. He has received payment on behalf of Jubilant DraxImage for expert witness testimony. Dr. Tillinghast: Activities related to the present article: No relevant relationships. Activities not related to the present article: Consultant for GE Healthcare and Siemens; institutional financial support to research from GE Healthcare and Siemens. Dr. Tillo: Activities related to the present article: No relevant relationships. Activities not related to the present article: Grants and Honoraria from Siemens and Roche. He has served as a paid advisor to Siemens, Philips, and GE Healthcare. Dr. Valgimigli: Activities related to the present article: Serves on the board of directors/governance committees of IONETIX, EDRNA, AARTI, and Demetra. He has received honorarium for educational activities from IQVIA. He has received payment on behalf of Jubilant DraxImage for expert witness testimony. Dr. Wallentin: Activities related to the present article: No relevant relationships. Activities not related to the present article: Serves on the board of directors/governance committees of EDRNA, AARTI, and Demetra. He has received honorarium for educational activities from IQVIA. He has received payment on behalf of Jubilant DraxImage for expert witness testimony. Dr. Yeh: Activities related to the present article: No relevant relationships. Activities not related to the present article: Consultant for GE Healthcare and Siemens; institutional financial support to research from GE Healthcare and Siemens. Dr. Zhu: Activities related to the present article: No relevant relationships. Activities not related to the present article: Consultant for GE Healthcare and Siemens; institutional financial support to research from GE Healthcare and Siemens.

References

1. Elkind MSV, Harrington RA, Benjamin IJ. Role of the American Heart Association in the Global COVID-19 Pandemic. Circulation 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.046749.
2. Welt FGP, Shah PB, Aronow HD et al. Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: from ACC’s interventional council and SCAI. J Am Coll Cardiol 2020. https://doi.org/10.1016/j.jacc.2020.03.021.
3. Szerlip M, Anwaruddin S, Aronow HD et al. Considerations for cardiac catheterization laboratory procedures during the COVID-19 pandemic: perspectives from the Society for Cardiovascular Angiography and Interventions Emerging Leader Mentorship (SCAI ELM) members and graduates. Cath Cardiovasc Interventions 2020. https://doi.org/10.1002/ccd.28887.
4. Choi AD, Abbara S, Branch KR et al. Use of cardiac computed tomography amidst the COVID-19 pandemic. J Cardiovasc Comput Tomogr 2020. https://doi.org/10.1016/j.jcct.2020.03.002.
5. ASE statement on protection of patients and echocardiography service providers during the 2019 novel coronavirus outbreak. https://www.ascheco.org/wp-content/uploads/20200303ASE-COVID-Statement-FINAL-1.pdf. Accessed 23 Mar 2020.
6. British Society of Echocardiography. Critical guidance regarding provision of echocardiography during the COVID-19 pandemic. https://bschoe.co/covid19. Accessed 23 Mar 2020.
7. Antonini-Canterin F, Pepi M, Monte I, et al. Documento ad uso degli operatori di ecografia cardiovascolare per COVID-19. Società Italiana di Echocardiografia e CardioVascular Imaging. https://www.siei.it/documento-ad-uso-dell-operatori-di-ecografia-cardiovascolare-per-covid-19/. Accessed 23 Mar 2020.
8. Society for Cardiovascular Magnetic Resonance. SCMR’s COVID-19 preparedness toolkit. https://scmr.org/page/COVID19. Accessed 26 Mar 2020.
9. Alhazzani W, Hylander Møller M, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of adults with coronavirus disease 2019 (COVID-19). Crit Care Med 2020. https://scm.org/getattachment/Disaster/SSC-COVID19-Critical-Care-Guidelines.pdf?lang=en-US&_zss=W5jdl1&_zll=jc6.
10. Driggel E, Madhavan MV, Bikdeli B et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 2019. https://doi.org/10.1016/j.jacc.2020.03.031.
11. Clerkin KJ, Fried JA, Raikhelkar J et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation 2019. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/critical-preparedness-readiness-and-response-actions-for-covid-19.pdf?lang=en-US&_zs=WSjjd1&_zl=j1cc6.
12. Interim guidance for healthcare facilities: preparing for community transmission of COVID-19 in the United States. https://www.cdc.gov/coronavirus/2019-ncov/healthcare-facilities/guidance-for-covid-19.html. Accessed 26 Mar 2020.
13. Bernheim A, Mei X, Yang Y et al. Chest CT findings in coronavirus disease-19 (COVID-19): Relationship to duration of infection. Radiology 2020. https://doi.org/10.1148/radiol.2020200463.

Additional resources

https://www.cdc.gov/coronavirus/2019-ncov/healthcare-facilities/step-s-to-prepare.html.
https://www.osha.gov/Publications/OSHA3990.pdf.
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/critical-preparedness-readiness-and-response-actions-for-covid-19.
https://www.ace.org/latest-in-cardiology/features/acca-coronavirus-disease-2019-covid-19-hub/sort=04fcommonsortdate90022%20desc.
https://www.cdc.gov/hai/pdfs/ppe/PPE-Sequence.pdf.
https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Guidance and best practices for nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An Information Statement from ASNC and SNMMI

Hicham Skali, Venkatesh L. Murthy, Mouaz H. Al-Mallah, Tim M. Bateman, Rob Beanlands, Nathan Better, Dennis A. Calnon, Vasken Dilsizian, Alessia Gimelli, Robert Pagnanelli, Donna M. Polk, Prem Soman, Randall C. Thompson, Andrew J. Einstein and Sharmila Dorbala

J Nucl Med.
Published online: May 15, 2020.
Doi: 10.2967/jnumed.120.246686

This article and updated information are available at:
http://jnm.snmjournals.org/content/early/2020/05/14/jnumed.120.246686.citation

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml

JNM ahead of print articles have been peer reviewed and accepted for publication in JNM. They have not been copyedited, nor have they appeared in a print or online issue of the journal. Once the accepted manuscripts appear in the JNM ahead of print area, they will be prepared for print and online publication, which includes copyediting, typesetting, proofreading, and author review. This process may lead to differences between the accepted version of the manuscript and the final, published version.